Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
JPWA Disbands Kumamoto Quake Disaster Response HQ
The Federation of Japan Pharmaceutical Wholesalers Association (JPWA) on September 10 disbanded the disaster response headquarters it had set up following the Kumamoto earthquake as pharmaceutical supplies in affected areas continue to stabilize.The JPWA said it will continue to work…
To read the full story
Related Article
- MHLW Gives Fuel Priority to Drug Deliveries in Quake-Hit Kumamoto
August 4, 2026
- Sanwa Kagaku Says Kumamoto Plant Remains Shut, Drug Supplies Stable
July 31, 2026
- Some Drug Plants Halt Operations after Kumamoto Temblor, Supplies Unaffected
July 30, 2026
- Pipe Damage Causes Water Leak at Sawai Plant after Quake: MHLW
July 30, 2026
- MHLW Urges Stable Supply of Drugs after Kumamoto Earthquake
July 30, 2026
- Kumamoto Quake Hits 46 Medical Facilities; No Pharma Damage Yet: MHLW
July 29, 2026
- Drug Makers, Wholesalers Rush to Gauge Kumamoto Quake Impact
July 29, 2026
ORGANIZATION
- JPWA Disbands Kumamoto Quake Disaster Response HQ
September 14, 2026
- BMS Prods Japan to Better Reward Regenerative Medicine Innovation
September 11, 2026
- Prix Galien to Launch Japan Awards in February 2027
September 8, 2026
- FPMAJ Lauds Drug Investment Push, Urges Budget Follow-Through
September 8, 2026
- UA Zensen Manufacturing Wage Hikes at 4.89%, Pharma in Mid-4% Range
September 4, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…